Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-020833
Filing Date
2025-02-14
Accepted
2025-02-14 13:09:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10075
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 121023
  Complete submission text file 0000950170-25-020833.txt   178761
Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902
Business Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902 9176446313
Channel Therapeutics Corp (Subject) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94460 | Film No.: 25626039
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)